Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Sinopharm Group Co., Ltd.    1099   CNE100000FN7

SINOPHARM GROUP CO., LTD.

(1099)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
15.9 16.2 16.9 16.96 17.82 Last
10261340 10019010 23811050 12526200 22156840 Volume
-1.12% +1.89% +4.32% +0.36% +5.07% Change
Financials
Sales 2020 462 B 68 773 M 68 773 M
Net income 2020 6 704 M 999 M 999 M
Net Debt 2020 15 485 M 2 307 M 2 307 M
P/E ratio 2020 7,05x
Yield 2020 4,21%
Sales 2021 524 B 78 036 M 78 036 M
Net income 2021 7 551 M 1 125 M 1 125 M
Net Debt 2021 21 271 M 3 169 M 3 169 M
P/E ratio 2021 6,27x
Yield 2021 4,63%
Capitalization 47 901 M 7 166 M 7 137 M
EV / Sales 2020 0,14x
EV / Sales 2021 0,13x
Nbr of Employees 93 764
Free-Float 43,0%
More Financials
Company
Sinopharm Group Company Limited is principally engaged in the distribution of pharmaceutical products and medical equipment. The Company operates through three business segments. The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics. The Retail Pharmacy segment is engaged in... 
More about the company
Notations Surperformance© of Sinopharm Group Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about SINOPHARM GROUP CO., LTD.
10/22SINOPHARM : Nine-Month Net Profit Rose 7.9%
DJ
10/20China's Sinovac vaccine to be included in Brazil's immunization program, gove..
RE
10/20China's Sinovac vaccine to be included in Brazil's immunization program, gove..
RE
10/20SINOPHARM GROUP CO., LTD. : quaterly earnings release
10/19Brazil's Butantan says tests show vaccine by China's Sinovac is safe
RE
10/15Coronavirus vaccine candidate from China's CNBG shows promise in human test, ..
RE
10/15China's Sinopharm offers experimental COVID-19 vaccines to students - WSJ
RE
09/27SINOPHARM : Announcements and Notices - ANNOUNCEMENT POLL RESULTS OF THE EXTRAOR..
PU
09/27SINOPHARM : Announcements and Notices - NOTICE OF EXTRAORDINARY GENERAL MEETING
PU
09/27SINOPHARM : Announcements and Notices - ANNOUNCEMENT ELECTION OF CHAIRMAN AND VI..
PU
09/27SINOPHARM : Announcements and Notices - List of Directors and Their Role and Fun..
PU
09/24China's Sinovac expects interim final-stage trial data on coronavirus vaccine..
RE
09/24China's CNBG to donate 200,000 coronavirus vaccine doses to medics in Wuhan
RE
09/24China's CNBG to donate 200,000 coronavirus vaccine doses to medics in Wuhan
RE
09/22Chinese state-backed firm expects coronavirus vaccine approval for public use..
RE
More news
News in other languages on SINOPHARM GROUP CO., LTD.
10/20SINOPHARM GROUP CO., LTD. : Veröffentlichung des Quartalsergebnisses
10/20SINOPHARM GROUP CO., LTD. : publication des résultats trimestriels
10/15VACCIN CONTRE LE COVID-19 : trop vite, trop haut, trop fort?
09/25CORONAVIRUS : la Chine espère produire 610 millions de doses/an de vaccins
09/15CORONAVIRUS : la Chine évoque un potentiel vaccin pour novembre
More news
Chart SINOPHARM GROUP CO., LTD.
Duration : Period :
Sinopharm Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOPHARM GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 23,07 CNY
Last Close Price 15,37 CNY
Spread / Highest target 136%
Spread / Average Target 50,1%
Spread / Lowest Target -6,24%
EPS Revisions
Managers
NameTitle
Yong Liu President & Executive Director
Fang Yao Chairman-Supervisory Board
Zhi Ming Li Chairman
Xiu Chang Jiang Chief Financial Officer & Vice President
Jin Dong Deng Non-Executive Director
Sector and Competitors